Skbloom

Novartis

https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis

Novartis Cosentyx receives FDA approval for treatment of children ...

Jun 1, 2021 ... Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis ... This is the first ...

https://www.cosentyx.com/

COSENTYX® (secukinumab) | Home Page

people 6 years of age and older with moderate to severe plaque psoriasis (PsO) ... Novartis reserves the right to rescind, revoke, or amend this program ...

Novartis

https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-eu-approval-first-line-systemic-treatment-pediatric-psoriasis

Novartis Cosentyx® receives EU approval for first-line systemic ...

Aug 3, 2020 ... ... psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS), over 100 studies and with more than 340,000 patients treated worldwide ...

https://www.uptodate.com/contents/psoriasis-beyond-the-basics/contributor-disclosure

Contributor disclosures - UpToDate

... [Psoriasis]; Janssen Pharmaceutica [Psoriasis]; LEO Pharma [Psoriasis]; Novartis [Psoriasis]; Pfizer [Psoriasis]; UCB [Psoriasis]. All of the relevant ...

Novartis United States of America

https://www.novartis.com/us-en/news/media-releases/fda-approves-novartis-cosentyx-first-intravenous-iv-formulation-interleukin-17a-antagonist-rheumatic-diseases

FDA approves Novartis Cosentyx® as first intravenous (IV ...

Oct 6, 2023 ... First new intravenous (IV) treatment option in six years for adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and ...

https://ngcs.novartis.com/tpcinterest.jsp

AREAS OF THERAPEUTIC INTEREST

Psoriasis; Psoriatic Arthritis; Transplant; Vascular Inflammation in CVD. Novartis Oncology Office of Grants and Education (OGE) OGE will receive and review ...

Novartis Philippines

https://www.novartis.com/ph-en/patient-resources/psoriasis

Psoriasis | Novartis Philippines

Psoriasis. Psoriasis is a chronic, non-communicable, painful, disfiguring and disabling disease for which there is no cure and with great negative impact on ...

Fierce Pharma

https://www.fiercepharma.com/marketing/novartis-standbys-cyndi-lauper-michelle-bernstein-unite-report-cosentyx-still-working

Novartis' celebrity standbys report Cosentyx is 'Still Working'

May 17, 2024 ... Nearly a decade into Cosentyx's tenure as an FDA-approved treatment for plaque psoriasis and psoriatic arthritis, Novartis has tapped two of ...

Novartis Philippines

https://www.novartis.com/ph-en/news/media-releases/novartis-secukinumab-first-and-only-il-17a-inhibitor-potentially-modify-course-psoriasis

Novartis' secukinumab is first and only IL-17A inhibitor to potentially ...

Basel, March 21, 2017 – Novartis today announced new data suggesting, for the first time, that secukinumab may modify the course of moderate-to-severe psoriasis ...

The New England Journal of Medicine

https://www.nejm.org/doi/full/10.1056/NEJMoa1314258

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials ...

Jul 9, 2014 ... Secukinumab (Novartis Pharmaceuticals) is a recombinant, high-affinity, fully human immunoglobulin G1κ monoclonal antibody that selectively ...

Recommendation

Recommendation